Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verve Therapeutics Inc (NQ: VERV )

14.42 +0.12 (+0.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,039,550
Open 14.52
Bid (Size) 14.16 (1)
Ask (Size) 14.78 (1)
Prev. Close 14.30
Today's Range 14.19 - 14.84
52wk Range 10.70 - 43.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
From Verve Therapeutics
Via Globe NewsWire
Verve Therapeutics's Return On Capital Employed Insights
 
Via Benzinga

Performance

YTD
-23.70%
-23.70%
1 Month
-20.73%
-20.73%
3 Month
-25.48%
-25.48%
6 Month
-58.02%
-58.02%
1 Year
-36.81%
-36.81%

More News

Read More
Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates
From Verve Therapeutics
Via Globe NewsWire
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
From Verve Therapeutics
Via Globe NewsWire
Better Buy: Beam Therapeutics or Intellia Therapeutics?
Via The Motley Fool
3 Deeply Undervalued Stocks That Could Double Your Money
Via The Motley Fool
Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia
From Verve Therapeutics
Via Globe NewsWire
Being Cautious On Regulatory/Commercial Path, This Analyst Initiates Coverage On Verve Therapeutics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
Via Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
Via InvestorPlace
Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away'
Via Benzinga
Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Verve Therapeutics
Via Globe NewsWire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
Via Investor's Business Daily
Analyst Beefs Up Beam Therapeutics Price Target, Says 'Reward Is Now Skewed To Upside'
Via Benzinga
Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
Cathie Wood Adds $7M Of This Clinical-Stage Biotech, Trims Stake In CVS-Target Signify Health
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
Via Benzinga
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Gold Down 1%; China Pharma Shares Spike Higher
Via Benzinga
VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday
Via Benzinga
US Stocks Start Week On Lower Note; Dow Tumbles 250 Points
Via Benzinga
Verve Therapeutics Stock Skids On The FDA's Long List Of Gene-Editing Concerns
Via Investor's Business Daily
Looking Into Verve Therapeutics's Recent Short Interest
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.